IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
Autoimmune Pivot | IGM Biosciences shifts focus to autoimmune diseases, discontinuing oncology programs to streamline operations and concentrate on promising T-cell engagers |
Pipeline Potential | Explore imvotamab's progress in rheumatoid arthritis and other autoimmune indications, with trials expanding and data readouts anticipated as key catalysts |
Market Outlook | Analyst price targets range from $17 to $20, reflecting cautious optimism about IGM's strategic shift and potential in the competitive autoimmune market |
Future Prospects | Learn how positive trial results could position IGM as a contender in autoimmune treatments, potentially leading to partnerships and validating their novel approach |
Metrics to compare | IGMS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIGMSPeersSector | |
---|---|---|---|---|
P/E Ratio | −2.8x | −1.6x | −0.7x | |
PEG Ratio | −0.11 | −0.01 | 0.00 | |
Price/Book | 7.8x | 1.0x | 2.6x | |
Price / LTM Sales | 210.1x | 10.5x | 3.2x | |
Upside (Analyst Target) | 94.0% | 322.9% | 47.0% | |
Fair Value Upside | Unlock | 18.7% | 7.5% | Unlock |